echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Rheumatology: Autologous stem cell transplantation mobilized with low-dose cyclophosphamide is feasible in patients with systemic sclerosis

    Rheumatology: Autologous stem cell transplantation mobilized with low-dose cyclophosphamide is feasible in patients with systemic sclerosis

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Objective: To evaluate the feasibility of reducing the dose of cyclophosphamide in patients with systemic sclerosis during high-dose chemotherapy and autologous stem cell transplantation before mobilizing chemotherap.


    Methods: This single-center study retrospectively analyzed 32 patients with systemic sclerosis who underwent autologous stem cell transplantatio.


    RESULTS: Higher doses of cyclophosphamide did not appear to be beneficial for stem cell collection, as there was no significant difference in stem cell yield between high and low doses of cyclophosphamide (2 vs 2*106/kg body weight after CD34+ enrichment .


    Higher doses of cyclophosphamide were likely to have more side effects, but the difference was not statistically significan.


    Lower body weight and body mass index (p<001) as well as pre-rituximab treatment (p<005) and cardiac involvement (p<001) may have negatively affected stem cell collection independently of the chosen regime.


    Conclusions: The data from this study suggest that a reduced cyclophosphamide dose mobilization regimen appears feasibl.


     

    Source:

    Pecher AC, Ach KR, Vogel W, Henes J.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.